menu search

Syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 3 years in patients with geographic atrophy (ga)

syfovre reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sha...

November 4, 2023, 5:37 pm

Apellis (apls) q3 loss wider than expected, syfovre drives sales

Apellis' (APLS) third-quarter 2023 bottom line misses estimates, while the top line beats the same. Newly approved product, Syfovre, drives sales in t...

November 2, 2023, 12:47 pm

Apellis pharmaceuticals reports third quarter 2023 financial results

Generated total revenues of $110.4 million in the third quarter, including $75.3 million for SYFOVRE® (pegcetacoplan injection) and $23.9 million for...

November 1, 2023, 11:05 am

Apellis announces preliminary u.s. net revenues of approximately $74 million for syfovre® (pegcetacoplan injection) in the third quarter of 2023

Continued strong demand, with more than 100,000 vials (commercial and sample) distributed to date; growth in week-over-week demand returned starting i...

October 5, 2023, 11:00 am

Lifshitz law pllc announces investigations of apellis pharmaceutics, inc. (nasdaq: apls), rtx corp. (nyse: rtx), live nation entertainment, inc. (nyse: lyv), and keycorp (nyse: key)

NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Lifshitz Law PLLC announces investigation into possible sec...

September 2, 2023, 11:00 pm

Apellis (apls) dips on layoffs amid syfovre safety issues

Apellis (APLS) plans to initiate restructuring plans to strengthen its commercial portfolio and curb cash burn....

August 30, 2023, 9:46 am

Biopharmaceutical stock soars on positive drug update

The shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) are soaring, after the biopharmaceutical concern identified the potential cause of an issue w...

August 23, 2023, 11:22 am

Why is apellis pharmaceuticals (apls) stock up 23% today?

Apellis Pharmaceuticals (NASDAQ: APLS ) stock is on the rise Wednesday after the biopharmaceutical company announced an update on injection kits. The...

August 23, 2023, 8:28 am

Apellis pharmaceuticals stock jumps on safety review update

Apellis Pharmaceuticals Inc (NASDAQ:APLS) jumped some 30% in Wednesday's premarket after last night updating investors on an ongoing safety review of ...

August 23, 2023, 7:52 am

Apellis (apls) focuses on empaveli to fuel its growth

Apellis' (APLS) first marketed product, Empaveli, continues to be the growth driver since its launch. However, ...

August 15, 2023, 10:55 am

Apellis (apls) q2 earnings top, syfovre sales boost revenues

Apellis (APLS) reports better-than-expected second-quarter 2023 results. However, the stock falls 20% due to ambiguity surrounding Syfovre's safety pr...

August 1, 2023, 11:55 am

Syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 30 months in patients with geographic atrophy (ga)

syfovre reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30 compared to projected s...

July 30, 2023, 5:00 pm

Apellis provides update on review of rare safety events with syfovre® (pegcetacoplan injection) for geographic atrophy

No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis Confirmed seven total events of non-occlusive...

July 29, 2023, 6:52 pm

First-to-market edge for apellis’s syfovre in geographic atrophy diminished in the face of an unexpected safety signal

Prospects for syfovre uptake and trust in Apellis take a plunge following reports of intraocular inflam...

July 28, 2023, 4:26 pm

Apellis (apls) plunges on safety issues with eye treatment

Apellis (APLS) suffers a setback on reports of six events of retinal vasculitis (or inflammation) following treatment with ...

July 19, 2023, 12:52 pm

Apellis: exercise caution in response to safety signal (rating downgrade)

Apellis Pharmaceuticals, Inc. shares dropped 37% following reports of eye inflammation cases related to its geographic atrophy treatment, Syfovre. The...

July 18, 2023, 10:08 am

Apellis (apls) q1 earnings miss, empaveli & syfovre fuel growth

Apellis Pharmaceuticals' (APLS) loss in the first quarter is wider than estimates. Empaveli and syfovre ...

May 5, 2023, 10:40 am

Top-notch biotech apellis soars after new drug obliterates sales views

Apellis' new eye drug, Syfovre, crushed expectations in its first quarter post launch, putting APLS stock on track to open at a record high. The post ...

May 5, 2023, 9:36 am

Apellis presents phase 3 functional analyses of syfovre™ (pegcetacoplan injection) for geographic atrophy

Showed visual function and quality-of-life benefits in patients with extrafoveal lesions Slowed the loss of retinal pigmented epithelial and photorece...

April 23, 2023, 10:05 pm

Apellis (apls) stock up 50% in three months: here's why?

Apellis (APLS) stock rises 50% in the past three months owing to the approval of syfovre (pegcetacoplan...

April 11, 2023, 12:16 pm


Search within

Pages Search Results: